DWA
ARCT icon

Dorsey Wright & Associates’s Arcturus Therapeutics ARCT Stock Holding History

Dorsey Wright & Associates’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-503
Closed -$7K – 314
2020
Q1 		$7K Buy
+503
New +$6.44K ﹤0.01% 213
2019
Q4 		– Sell
-1,034
Closed -$11K – 273
2019
Q3 		$11K Buy
+1,034
New +$11.2K ﹤0.01% 208

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Dorsey Wright & Associates's ARCT Position: Q2 2020 in Review

Dorsey Wright & Associates sold out of Arcturus Therapeutics (ARCT) in Q2 2020, closing a stake of 503 shares — an estimated $7K sold.

Dorsey Wright & Associates first reported a position in ARCT in Q3 2019 and held it in 2 quarters. The position peaked at $11K in Q3 2019. 114 funds tracked by Wall St. Rank hold ARCT as of Q2 2020.

  • Dorsey Wright & Associates reported no remaining Arcturus Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 503 Arcturus Therapeutics shares in Q2 2020, an estimated $7K.
  • Dorsey Wright & Associates first reported a position in Arcturus Therapeutics in Q3 2019 and held it in 2 quarters.
  • Dorsey Wright & Associates's Arcturus Therapeutics position peaked at $11K in Q3 2019.
  • 114 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2020.

Based on Dorsey Wright & Associates's 13F filing for Q2 2020, filed 23 Jul 2020.